SNAP Update and ResourcesActualización y recursos de SNAP
On November 1, 2025, the requirements to receive and apply to the Supplemental Nutrition Assistance Program (SNAP) benefits have changed. To see the new policies to request SNAP benefits, click here and/or call 211 for SNAP assistance. Learn more
El 1 de noviembre de 2025, cambiaron los requisitos para recibir y aplicar para los beneficios del Programa de Asistencia Nutricional Suplementaria (SNAP, por sus siglas en inglés). Para consultar las nuevas políticas para aplicar para los beneficios de SNAP, haz clic aquí o llama al 211 para obtener ayuda de SNAP. Aprende Más
Transportation UpdateActualización de transporte
Starting December 15, 2025, SafeRide Health will become the new provider for all member rides to doctor appointments and pharmacy visits. After this date, Texas Children’s Health Plan will no longer use MTM for Non Emergency Medical Transportation (NEMT) services.
For other questions, please call Member Services at the number on the back of your member ID card.
A partir del 15 de diciembre de 2025, SafeRide Health será el nuevo proveedor para todos los viajes de los miembros a citas médicas y visitas a la farmacia. Después de esta fecha, Texas Children’s Health Plan ya no usará MTM para los servicios de Transporte Médico No Urgente (NEMT).
Change in Preferred Drug List Status for Glucocorticoids, Inhaled Drug Class
Date: December 8, 2023
Attention: Providers
Effective date: December 15, 2023
Call to action: Effective December 15, 2023, the Texas Health and Human Services (HHS) removed non-preferred status from generic fluticasone hydrofluoroalkane (HFA) and brand Qvar products on the preferred drug list. This is in response to the discontinuation of the product by the manufacturer.
The preferred status of the brand name Flovent HFA and Flovent Diskus will not change to allow for any remaining stock to be used.
How this impacts providers: The change will allow providers to prescribe the generic fluticasone HFA and brand QVAR products without requiring PDL prior authorization at this time and continue accessing necessary medication for their patients.
Please see below for the list of impacted drugs (of note, the approval is NDC-specific):
Preferred Medication
Preferred Medication NDC
Type of Change
Effective Date
FLUTICASONE PROP HFA 44 MCG
66993007896
Generic now preferred
December 15, 2023
FLUTICASONE PROP HFA 110 MCG
66993007996
Generic now preferred
December 15, 2023
FLUTICASONE PROP HFA 220 MCG
66993008096
Generic now preferred
December 15, 2023
QVAR REDIHALER 40 MCG
59310030240
Brand now preferred
December 15, 2023
QVAR REDIHALER 80 MCG
59310030480
Brand now preferred
December 15, 2023
FLOVENT HFA
Brand remains preferred
FLOVENT DISKUS
Brand remains preferred
Update as of 1/11/2024: Flovent shortage notices to announce this change to your patients/our members:
Next step for Providers: Prescribers are encouraged to proactively obtain a prescription for the preferred alternatives to avoid disruption in patient’s therapy. Prescribers should share this communication with their staff.
